Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ElevateBio

Explore full profile

Accelerating the rate of innovation and success in cell and gene therapy with a disruptive capital-efficient model

Waltham, United StatesFounded 2018Biotech & Life Sciences
Valuation $2.5–5B Last recorded · 2026
Headcount 100–500 Current team size
Unlock exact values This page shows ranges. Dealroom has the exact numbers for ElevateBio and the history behind them.

At a glance

Founded
2018
Headquarters
Waltham, United States
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Samsara BioCapital
  • Redmile Group
  • F2 Ventures
  • EcoR1 Capital
  • MPM BioImpact

Series B and later15 investors entered at this stage

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99.5%
🇮🇳 India0.3%
2 countries shown
Web traffic by country
39K monthly visits
across markets
🇺🇸 United States90.3%
🇬🇧 United Kingdom3.8%
🇮🇳 India3.1%
🇫🇷 France1.8%
Top 4 markets shown

Patents

Estimated portfolio value
$29M

10 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where ElevateBio was the backer or acquirer, 2021–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across ElevateBio's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where ElevateBio deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        ElevateBio's portfolio, mapped.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about ElevateBio on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See ElevateBio on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles